Sillajen and Transgene bid to revive the oncolytic virus craze
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Readouts approach for biggest Huntington’s hopes
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
First big test approaches for Urovant
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Krystal gets more skin in the epidermolysis bullosa game
Krystal Biotech shares surged after positive data with its epidermolysis bullosa project, KB103, in just two patients. Now it needs to repeat the trick.
Intercept’s big Nash day draws near
Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
Darzalex's ambitions extend beyond Maia
Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.
Moment of truth for Sarepta and Myonexus
A limb-girdle muscular dystrophy gene therapy Sarepta licensed last year faces its first clinical test.
Solid guns for Sarepta
Solid Biosciences should soon find out if its DMD gene therapy, SGT-001, could compete with Sarepta’s.
Combination trial could be start of second act for Amgen’s Imlygic
Masterkey-265 will test the sector’s renewed interest in oncolytic viruses as a way of turning “cold" tumours "hot”.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.